Key clinical point: The oral alkylating agent trofosfamide showed efficacy in a small number of elderly patients with untreated metastatic soft-tissue sarcomas.
Major finding: In a randomized phase 2 trial that compared trofosfamide with doxorubicin (Adriamycin), the 6-month progression-free survival (PFS) rate with trofosfamide, the primary endpoint, was 27. 6% versus 35.9% in the doxorubicin arm.
Study details: Randomized phase 2 trial comparing trofosfamide with doxorubicin in 120 elderly patients with histologically confirmed metastatic soft-tissue sarcomas with no prior first-line chemotherapy and with adequate bone marrow, renal, and liver functionelderly patients with previously untreated .
Disclosures: The trial was supported by Baxter Oncology of Germany. Dr. Hartmann reported having no conflicts of interest to disclose.
Source: Hartman JT et al. ASCO 2018, Abstract 11507.
Hartman JT et al. ASCO 2018, Abstract 11507.
This Week's Must Reads
Program reduces ER admissions and inpatient costs, Mendenhall M et al. Quality Care Symposium, Abstract 30
Pain severity decreased over time with app, Kamdar MM et al. PallOnc 2018, Abstract 76
National health care spending growth slowed to 3.9% in 2017 , Martin A et al. Health Affairs. 2018. doi: 10.1377/hlthaff.2018.05085
Medicare Part D rules on protected medication classes could change, Federal Register (83 FR 62152)
Federal proposal aims to move doctors back to face-to-face interventions, Office of the National Coordinator for Health IT
Must Reads in Sarcoma & GIST
Vanderbilt staging best for predicting overall survival in retroperitoneal sarcoma, Huggett B & Cates J. Modern Pathology; 5 Nov. 2018. https://www.nature.com/articles/s41379-018-0166-8
Nivolumab, pembrolizumab successfully used in Kaposi sarcoma, Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.
Perioperative radiation therapy underused in elderly patients with soft tissue sarcomas, Venigalla S et al. Intl J Rad Oncology*Biology*Physics; September (102) 2018: 155-165. https://doi.org/10.1016/j.ijrobp.2018.05.019
Age, R0 resection, and adjuvant radiotherapy boost outcomes in myxofibrosarcoma, Boughzala-Bennadji R et al. Intl J Rad Oncology*Biology*Physics; October (102) 2018: 399-406. https://doi.org/10.1016/j.ijrobp.2018.05.055
Tumor size, invasion beyond subcutaneous fat predict adverse outcomes in undifferentiated pleomorphic sarcoma, Winchester D et al. J Am Acad Dermatol. Available online 19 May 2018 https://doi.org/10.1016/j.jaad.2018.05.022